WORCESTER, Mass., June 1, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that the results of a recently completed Phase I trial in prostate cancer patients of the novel immunotherapeutic peptide AE37 were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (www.asco.org) held in Orlando from May 29 to June 2, 2009. The studies were conducted in Athens, Greece under the direction of Dr. Constantin Baxevanis. The immunotherapeutic peptide AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
